Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 8068

Next Previous
X
Search
Drug Profile

SHR 8068

Alternative Names: SHR-8068

Latest Information Update: 07 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Gastric cancer; Oesophageal cancer
  • Phase I/II Liver cancer; Non-small cell lung cancer

Most Recent Events

  • 01 Oct 2024 Suzhou Suncadia Biopharmaceuticals plans a phase III trial for Liver cancer (Late-stage disease, Inoperable/Unresectable, Combination therapy, Metastatic disease, First line therapy) in China (IV) (NCT06618664)
  • 02 Jul 2024 Phase-II clinical trials in Biliary cancer (First-line therapy, Late-stage disease, Combination therapy, Metastatic disease, Recurrent) in China (IV) (NCT06465563)
  • 20 Jun 2024 Suzhou Suncadia Biopharmaceuticals plans a phase II trial for Biliary cancer (First-line treatment, Late-stage disease, Combination therapy, Metastatic disease, Recurrent) (IV) in July 2024(NCT06465563)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top